Neurocrine presents encouraging three-year data for Parkinson’s treatment
Neurocrine Biosciences Inc. (NBIX) reported that its data from PD-1101 study has demonstrated sustained improvement in motor function in patients with Parkinson’s disease. This Phase Ib open-label, three-year efficacy and safety study used investigational gene therapy, NBIb-1817. The average ‘Off’ time was also reduced by up to -1.91 hours while improved average “On” time without troublesome dyskinesia by up to +2.23 hours. Neurocrine is collaborating with Voyager Therapeutics Inc. (VYGR) for this study.
The data showed that the drug candidate was able to